2. Search Result
Search Result
Isoforms Recommended: CYP11
Results for "

CYP11B1

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16276
    Osilodrostat
    4 Publications Verification

    LCI699

    		 Mineralocorticoid Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat
  • HY-135794
    11-Ketodihydrotestosterone
    1 Publications Verification

    11-KDHT; 5α-Dihydro-11-keto testosterone

    		 Androgen Receptor Endocrinology
    11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells .
    11-Ketodihydrotestosterone
  • HY-B0105B
    Levoketoconazole
    1 Publications Verification

    (-)-Ketoconazole; (-)-Ketoconazol; (-)-R 41400

    		 Cytochrome P450 Infection Inflammation/Immunology
    Levoketoconazole ((-)-Ketoconazole) is the 2S,4R enantiomer derived from racemic Ketoconazole (HY-B0105). Levoketoconazole is a potent and orally active cortisol synthesis inhibitor. Levoketoconazole inhibits key steps in cortisol and testosterone synthesis by inhibiting CYP11B1, CYP11A1, and CYP17A1. Levoketoconazole can be used for research on endogenous Cushing’s syndrome .
    Levoketoconazole
  • HY-16276A
    Osilodrostat phosphate
    4 Publications Verification

    LCI699 phosphate

    		 Mineralocorticoid Receptor Cardiovascular Disease Cancer
    Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. Osilodrostat phosphate has blood pressure lowering ability. Osilodrostat phosphate can be used for research of Cushing syndrome (CS) .
    Osilodrostat phosphate
  • HY-163689
    Vicadrostat

    BI 690517

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Vicadrostat (BI 690517) is an orally active aldosterone synthase (aldosterone synthase) inhibitor, with IC50 values of 19 nM, 16 nM, and 18 μM against human, cynomolgus monkey, and rat aldosterone synthase, respectively. Vicadrostat has an in vivo IC50 of 25 nM for aldosterone synthesis. Vicadrostat exhibits high selectivity for cortisol synthase; it reduces aldosterone production and decreases plasma aldosterone levels. Vicadrostat can be used in the research of chronic kidney disease, heart failure, and hypertension .
    Vicadrostat
  • HY-113986
    Dexfadrostat

    (R)-Fadrozole; (R)-CGS 16949A free base; FAD286

    		 Cytochrome P450 Cardiovascular Disease
    Dexfadrostat ((R)-Fadrozole) is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat can be used for the research of breast cancer, primary aldosteronism, and hypertension .
    Dexfadrostat
  • HY-101217
    BI 689648

    		Cytochrome P450 Endocrinology
    BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.
    BI 689648
  • HY-RS17315
    Cyp11b1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11b1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp11b1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11b1 Mouse Pre-designed siRNA Set A
    Cyp11b1 Mouse Pre-designed siRNA Set A
  • HY-151140
    CYP11B1-IN-2

    		Cytochrome P450 Others
    CYP11B1-IN-2 (compound 7aa) is an orally active, potent and selective CYP11B1 inhibitor, with IC50 values of 9 nM and 25 nM for human CYP11B1 and rat CYP11B1, respectively. CYP11B1-IN-2 can be used for the research of diseases caused by excessive cortisol .
    CYP11B1-IN-2
  • HY-RS03435
    CYP11B1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CYP11B1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP11B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP11B1 Human Pre-designed siRNA Set A
    CYP11B1 Human Pre-designed siRNA Set A
  • HY-RS23770
    Cyp11b1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Cyp11b1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cyp11b1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp11b1 Rat Pre-designed siRNA Set A
    Cyp11b1 Rat Pre-designed siRNA Set A
  • HY-135281
    CYP11B2-IN-1

    		Cytochrome P450 Cardiovascular Disease
    CYP11B2-IN-1 is a CYP11B2 inhibitor with an IC50 of 2.3 nM. CYP11B2-IN-1 inhibits CYP11B1 with an IC50 of 142 nM .
    CYP11B2-IN-1
  • HY-122744
    CYP11B1-IN-1

    		Cytochrome P450 Metabolic Disease Cancer
    CYP11B1-IN-1 (Compound 25) is a selective, orally active hCYP11B1 inhibitor, with an IC50 of 2 nM against hCYP11B1 and an IC50 of 1.8 μM against rat CYP11B1. CYP11B1-IN-1 can be used for the research of Cushing's disease .
    CYP11B1-IN-1
  • HY-163751
    STING-IN-9

    		Mineralocorticoid Receptor Metabolic Disease
    STING-IN-9 (compound 2) is a potent inhibitor of human CYP11B2. STING-IN-9 showed more than 80 times higher selectivity over human CYP11B1 in vitro .
    STING-IN-9
  • HY-16276R
    Osilodrostat (Standard)

    LCI699 (Standard)

    		 Mineralocorticoid Receptor Reference Standards Cardiovascular Disease Inflammation/Immunology Cancer
    Osilodrostat (Standard) is the analytical standard of Osilodrostat. This product is intended for research and analytical applications. Osilodrostat (LCI699) is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat inhibits aldosterone and corticosterone synthesis. Osilodrostat has blood pressure lowering ability. Osilodrostat can be used for research of Cushing syndrome (CS) .
    Osilodrostat (Standard)
  • HY-176480
    CYP11B2-IN-3

    		Cytochrome P450 Cardiovascular Disease
    CYP11B2-IN-3 (compound 32) is an orally active and selective CYP11B2 inhibitor with IC50 values of 12.92 nM and 2341 nM for CYP11B2 and CYP11B1, respectively. CYP11B2-IN-3 can be used for study of hypertension .
    CYP11B2-IN-3
  • HY-135794R
    11-Ketodihydrotestosterone (Standard)

    11-KDHT (Standard); 5α-Dihydro-11-keto testosterone (Standard)

    		 Reference Standards Androgen Receptor Endocrinology
    11-Ketodihydrotestosterone (Standard) is the analytical standard of 11-Ketodihydrotestosterone. This product is intended for research and analytical applications. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells .
    11-Ketodihydrotestosterone (Standard)
  • HY-101217R
    BI 689648 (Standard)

    		Cytochrome P450 Reference Standards Endocrinology
    BI 689648 (Standard) is the analytical standard of BI 689648 (HY-101217). This product is intended for research and analytical applications. BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.
    BI 689648 (Standard)
  • HY-116666
    Etomidate acid

    		Drug Derivative Metabolic Disease
    Etomidate acid (Compound 35) is an etomidate analog. Etomidate acid inhibits the binding of metyrapone (Metyrapol) and 4-iodometomidate to rat adrenal membrane sites .
    Etomidate acid
  • HY-113986C
    Dexfadrostat hydrochloride

    (R)-Fadrozole hydrochloride; (R)-CGS 16949A; FAD286 hydrochloride

    		 Cytochrome P450 Cardiovascular Disease Cancer
    Dexfadrostat ((R)-Fadrozole) hydrochloride is an orally active and selective aromatase inhibitor, with human aromatase IC50 values of 6.4 nM. Dexfadrostat hydrochloride suppresses estrogen synthesis, reduces circulating estradiol levels and suppresses aldosterone production. Dexfadrostat hydrochloride can be used for the research of breast cancer, primary aldosteronism, and hypertension .
    Dexfadrostat hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: